EchoNous provides medical equipment services. It develops devices that help monitor and assess heart, lung, and abdominal assessments with the help of artificial intelligence and machine learning. The company was founded in 2016 and is based in Redmond, Washington.
ESPs containing EchoNous
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The portable ultrasounds market provides healthcare professionals with the ability to perform ultrasound exams in a variety of settings, including physician offices, clinics, hospitals, and even in the field. Portable ultrasound systems offer the same imaging quality as traditional systems, but in a much smaller and more convenient package. Many vendors use AI algorithms to automate the imaging pr…
EchoNous's Products & Differentiators
Torso provides real-time synchronization of three signals — a stethoscope, ECG, and ultrasound — all in one, easy to use handheld.
Research containing EchoNous
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned EchoNous in 1 CB Insights research brief, most recently on Mar 31, 2023.
Expert Collections containing EchoNous
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
EchoNous is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
EchoNous has filed 42 patents.
Medical imaging, Mathematical optimization, Continuum mechanics, Elasticity (physics), Solid mechanics
Medical imaging, Mathematical optimization, Continuum mechanics, Elasticity (physics), Solid mechanics
Latest EchoNous News
Jan 18, 2024
Australia and New Zealand Point-of-Care Diagnostic Ultrasound Market Size and Forecast (2020 - 2030), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (2D, 3D/4D, and Others), Portability (Trolley and Compact/Handheld), Application (General Imaging, Surgery, Cardiology, and Others), and End User (Emergency Department, Intensive Care Critical Care, Operating Theatre, IVF Clinics, Physiotherapy Centers, Sports Medicine, General Practitioner, Respiratory Center, Anesthesia, and General Wards) Publication Month : Jan 2024 Analyst’s Viewpoint Point-of-care ultrasound (POCUS) has been adopted at a growing rate in emergency departments across Australia and New Zealand and is now considered to be a fundamental competency of emergency physicians. Technological advancements have the potential to reduce the negative impact of healthcare access and availability issues in rural and remote areas of Australia. It is highly possible that technology will advance further, and a wider range of users will have access to compact, handheld, and portable ultrasound machines. A wider variety of different POCUS devices are available in Australian healthcare facilities compared to the past. The Cairns Hospital in Queensland, Australia, has implemented the state-of-the-art Mindray TEX20 latest high-end POC ultrasound, enabling emergency clinicians to address obstacles, such as scarce resources, diverse patient populations, and lack of follow-up care. The growing number of elective surgeries and emergencies generate the demand for more safe, accurate, and real-time diagnosis of various conditions by utilizing POC ultrasound. However, the shortage of skilled technicians impacts the Australia and New Zealand point-of-care diagnostic ultrasound market forecast during 2022-2030. Market Insights The growing incidence of chronic diseases and the number of patients requiring emergency care due to various health ailments, such as acute abdominal pain, urology problems, and immense chest pain, surge the demand for point-of-care ultrasound (POCUS) devices. POCUS facilitates patient care, improves medical procedure efficacy, decreases complications, and saves crucial time. The accuracy of POCUS in diagnosing pulmonary conditions is equivalent to or even higher than laboratory markers in diagnosing specific pulmonary conditions. Therefore, the growing incidence of these diseases and patients needing emergency care is expected to act as one of the major drivers for the Australia and New Zealand point-of-care diagnostic ultrasound market forecast. POCUS has been widely used in many disciplines as a rapid diagnostic tool, especially in emergency medicine. POCUS allows physician assistants (PAs) or nurse practitioners (NPs) in the emergency department to immediately acquire, interpret, and clinically integrate ultrasonographic imaging. In the emergency department, various clinical applications such as FAST exam, focussed echo, lung sonography, fluid drainage, and several other procedures can be performed with the help of these devices. POCUS has been used to aid in the diagnosis of multiple medical conditions ranging from acute appendicitis, airway compromise, and abdominal aortic aneurysm to traumatic injury assessment. Therefore, it is important for emergency departments to have POCUS so that they can be efficient, effective, and equipped to handle all kinds of emergencies. POCUS relatively fast use has made it a potential option where a formal radiological investigation may delay the diagnosis. Thus, point-of-care diagnostic ultrasound is increasingly adopted in emergency care, thereby driving the Australia and New Zealand point-of-care diagnostic ultrasound market growth during the forecast period. Future Trend Ultrasound equipment is beginning to incorporate robotics, cloud computing, 5G networks, artificial intelligence (AI), and remote technologies. Over time, ultrasound systems have developed into advanced terminal platforms with strong imaging and communication capabilities. Furthermore, specialized ultrasound equipment is typically more needed and appropriate to fulfill the growing needs and specifications of many clinical specializations and departments. Tele-remote POCUS is the technique of acquiring, storing, transmitting, analyzing, and processing photographs remotely by digitally reconstructing POCUS images using contemporary computers, network connectivity, and multimedia technologies. Through high-precision synchronization, remote real-time diagnostic and interventional procedures via text, audio, video, and other multi-channel connections can be enabled. Such technologies in the field of POCUS are anticipated to boost the Australia and New Zealand point-of-care diagnostic ultrasound market size. The real-time, long-distance, high-resolution, high-bandwidth, low-latency requirements for robotic operation and remote ultrasound consultation have been met in recent years by developing 5G technology, which makes it possible to transmit POCUS imaging in high quality and share it as a valuable medical resource. This opens the door to the possibility of tele-remote POCUS technology being used widely. Thus, the increasing adoption of automation in point-of-care ultrasound is anticipated to drive the Australia and New Zealand point-of-care diagnostic ultrasound market growth in the future. Customize Research To Suit Your Requirement We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making. Strategic Insights Market Size Value by Growth rate Forecast Period Have a question? Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any. Report Segmentation and Scope The "Australia and New Zealand Point-of-Care Diagnostic Ultrasound Market" is segmented on the basis of technology, portability, application, and end user. Based on technology, the market is segmented into 2D, 3D/4D, and others. Based on portability, the market is bifurcated into trolley and compact/handheld. In terms of application, the Australia and New Zealand point-of-care diagnostic ultrasound market is categorized into general imaging, cardiology, surgery, and others. Based on the end user, the market is segmented into emergency, intensive care/critical care, operating theater, IVF clinics, physiotherapy centers, sports medicine , general practitioners, respiratory centers, anesthesia, and general wards. Download Free Sample Request discounts available for Start-Ups & Universities Technology-Based Insights Based on technology, the Australia and New Zealand point-of-care diagnostic ultrasound market is segmented into 2D, 3D/4D, and others. The 2D segment held the largest Australia and New Zealand point-of-care diagnostic ultrasound market share in 2022. The 3D/4D segment is anticipated to register the highest CAGR from 2022 to 2030. In ultrasound, B-Mode is a setting that creates a two-dimensional (2D) greyscale image on the ultrasound screen and is the most commonly used mode. It is generally called 2D mode. The 2D ultrasound systems are readily available in the market and are affordable. 2D ultrasounds use high-frequency, non-ionized sound waves that are transmitted and received on one plane. Generally, 2D ultrasound is used to diagnose the health of the fetus in pregnant women. It produces a black-and-white image that shows the skeletal structure of the baby and makes the internal organs visible. The 2D image produced by point-of-care ultrasound (POCUS) allows healthcare professionals to visualize organs, blood vessels, and other structures in real time, helping with diagnosis and guiding procedures. 2D ultrasound is easier to use, time-efficient, and cost-effective compared to other technologies. In addition, advanced image quality and rapid results lead to the usage of this technology in diagnostic centers. Portability-Based Insights Based on portability, the Australia and New Zealand point-of-care diagnostic ultrasound market is bifurcated into trolley and compact/handheld. The trolley segment held a larger Australia and New Zealand point-of-care diagnostic ultrasound market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Trolley-based ultrasound is a portable ultrasound equipment often used in medical settings for diagnostic imaging purposes. It allows healthcare professionals to conveniently diagnose bedridden patients at the bedside without interrupting their treatment. Trolley-based diagnostic ultrasounds are convenient to move from one location to another in hospitals and diagnostic centers. These devices are suitable for monitoring fetuses and patients. The cost-effectiveness of the system and the fact that it does not require more space make it a popular adoption choice for small clinics and physicians. The system’s versatility, user-friendly features, higher adoption of imaging techniques to diagnose diseases, and the increased use of trolley-based ultrasound in acute care and emergency care settings support the growth of the segment in the Australia and New Zealand point-of-care diagnostic ultrasound market. Application-Based Insights In terms of application, the Australia and New Zealand point-of-care diagnostic ultrasound market is categorized into general imaging, cardiology, surgery, and others. The cardiology segment held the largest Australia and New Zealand point-of-care diagnostic ultrasound market share in 2022. The general imaging segment is anticipated to register the highest CAGR during 2022–2030. POC ultrasound refers to using portable ultrasound devices by healthcare providers at the patient’s bedside or in the clinical setting. In general imaging, POC ultrasound provides real-time visualization and aids in the diagnosis of various medical conditions. It offers accessibility and portability for various medical settings. Its compact and portable nature allows healthcare providers to perform imaging studies at the patient’s bedside, making it easier to assess different anatomical structures and organ systems in real time. Moreover, POC ultrasound is cost-effective, enhances patient care, improves diagnosis speed, and enhances the efficiency and accuracy of medical evaluations in general imaging. It serves as a rapid and accessible tool for initial assessment, guiding further diagnostics and treatment decisions. End User-Based Insights Based on end user, the Australia and New Zealand point-of-care diagnostic ultrasound market is segmented into emergency, intensive care/critical care, operating theater, IVF clinics, physiotherapy centers, sports medicine, general practitioners, respiratory centers, anesthesia, and general wards. The emergency department segment held the largest Australia and New Zealand point-of-care diagnostic ultrasound market share in 2022 and is anticipated to register the highest CAGR during the forecast period. Australia and New Zealand Point-of-Care Diagnostic Ultrasound market, by End User – 2022 and 2030 Request discounts available for Start-Ups & Universities Country Analysis Traditionally, ultrasound was the domain of sonographers, specialist radiologists, and cardiologists. This has changed with the introduction of point-of-care ultrasound, which is now used in various specialties for both diagnosis and procedure guidance. Australian rural doctors consider obstetric scanning to be an important component of their POCUS practice. Pregnant women in rural and remote Australia have less access to timely ultrasound services compared to women in metropolitan and regional areas due to a chronic shortage of trained sonographers. According to the Australian Institute of Health and Welfare cancer data 2021, cancer is a major cause of illness and death in the country. In 2021, ~151,000 new cancer cases were diagnosed in Australians—an average of 413 cases per day. In the same year, ~49,000 people succumbed to death due to cancer in the country—an average of 135 deaths per day. In addition, colorectal cancer is estimated to be the fourth most diagnosed cancer in the country in 2023, with around 15,400 cases reported that year. POCUS has proved to be an accurate technique for the diagnosis of gastrointestinal cancers. Therefore, the above-mentioned factors support the growth of the Australia and New Zealand point-of-care diagnostic ultrasound market in the region during the forecast period. The report profiles leading players operating in the Australia and New Zealand point-of-care diagnostic ultrasound market. These include GE Healthcare; Butterfly Network, Inc.; Fujifilm; Esoate SpA; Hologic, Inc; Echonous Inc; Koninklijke Philips NV; Shenzhen Mindray Bio-medical Electronics Co Ltd; and Clarius Mobile Health Corp. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers and subsequently increase their market share. Industry Developments and Future Opportunities : In January 2021, Hologic Inc. expanded its ultrasound portfolio by launching a new SuperSonic MACH 20 ultrasound system. Hologic Inc. offers three ultrasound technology tiers that ensure more facilities have access to customized ultrasound solutions to address their unique imaging needs. The systems are designed to increase efficiency and diagnostic accuracy, feature high-quality images and innovative imaging modes, and offer an intuitive user experience. In July 2020, FUJIFILM Sonosite, Inc. launched the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor. In March 2020, EchoNous Inc. announced FDA approval of its KOSMOS Platform, which consists of a distinctive 8oz. Ultrasound-based tools are combined with deep learning for clinical assessment of the heart, lungs, and abdomen. It is the first tool in medicine to apply the mathematical framework of machine learning to mimic the human learning and decision-making process. Report Coverage Segment Covered Regional Scope Country Scope Frequently Asked Questions Australia is estimated to hold the largest share of the market. The market growth in the country is attributed to the rising number of chronic diseases that necessitate quick and efficient diagnosis tools like POCUS for timely identification, evaluation, and management. The Australia and New Zealand point-of-care diagnostic ultrasound market is segmented on the basis of technology, portability, application, and end user. Based on technology, the market is segmented into 2D, 3D/4D, and others. Based on portability, the market is bifurcated into trolley and compact/handheld. In terms of application, the Australia and New Zealand point-of-care diagnostic ultrasound market is categorized into general imaging, cardiology, surgery, and others. Based on end user, the market is segmented into emergency, intensive care/critical care, operating theater, IVF clinics, physiotherapy centers, sports medicine, general practitioners, respiratory centers, anesthesia, and general wards. The List of Companies - Australia and New Zealand Point-of-Care Diagnostic Ultrasound Market Hologic Inc Clarius Mobile Health Corp Butterfly Network Inc. The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review. Data Collection and Secondary Research: As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain. Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends. Primary Research: The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team. For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise. A typical research interview fulfils the following functions: Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook Validates and strengthens in-house secondary research findings Develops the analysis team’s expertise and market understanding Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to: Industry participants: VPs, business development managers, market intelligence managers and national sales managers Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry. Below is the breakup of our primary respondents by company, designation, and region: Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection. Data Analysis: Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level. 3.1 Macro-Economic Factor Analysis: We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities. 3.2 Country Level Data: Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential. 3.3 Company Profile: The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size. 3.4 Developing Base Number: Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis. Data Triangulation and Final Review: The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization. We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports. We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time. Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out. Submit
EchoNous Frequently Asked Questions (FAQ)
When was EchoNous founded?
EchoNous was founded in 2016.
Where is EchoNous's headquarters?
EchoNous's headquarters is located at 8310, 154th Avenue North East, Redmond.
What is EchoNous's latest funding round?
EchoNous's latest funding round is Series D - II.
How much did EchoNous raise?
EchoNous raised a total of $124M.
Who are the investors of EchoNous?
Investors of EchoNous include Kennedy Lewis Investment Management and NVIDIA Inception Program.
Who are EchoNous's competitors?
Competitors of EchoNous include Caption Health and 1 more.
What products does EchoNous offer?
EchoNous's products include Kosmos Torso and 3 more.
Who are EchoNous's customers?
Customers of EchoNous include Johns HJohns Hopkins School of Medicineopkins.
Compare EchoNous to Competitors
Ultromics provides an artificial intelligence (AI)-based echocardiography imaging analysis platform. The company provides software solutions such as the EchoGo product, which enhances the accuracy of the diagnosis of cardiovascular situations and provides reports for clinicians without any need for physical software on-site. The company was founded in 2017 and is based in Oxford, United Kingdom.
Ultrasight develops of artificial intelligence (AI)-driven software in the healthcare sector. The company provides real-time guidance and quality assessment for healthcare professionals to perform high-quality cardiac ultrasounds in various settings. It primarily serves the healthcare industry, with a particular focus on emergency medicine and out-of-hospital care. Ultralight was formerly known as On-Sight Medical. It was founded in 2018 and is based in Ness Ziona, Israel.
SmartAlpha is a company focused on the intersection of artificial intelligence and healthcare, specifically in the domain of medical imaging. The company's main offering is an AI technology that transforms grayscale ultrasound images into intuitive and anatomy-aware ones in real-time, enabling healthcare professionals to perform ultrasound scans in diverse healthcare settings. The company primarily sells to the healthcare industry, with a particular focus on medical imaging and ultrasound technology. It was founded in 2019 and is based in Ankara, Turkey.
Us2.ai operates as an online healthcare technology platform. The company provides automated echo reports with disease detection. It uses a heart risk detection tool to improve patient outcomes and expand healthcare access. It was formerly known as eko.ai. The company was founded in 2017 and is based in Singapore.
Pons is a company focused on digital health, specifically in the medical imaging sector. The company's main offering is an AI-driven mobile ultrasound technology that enables individuals with limited medical background to perform ultrasound imaging and monitor chronic disease progress outside of hospital settings. This technology is primarily targeted towards the healthcare industry. It was founded in 2019 and is based in Brooklyn, New York.
Sonio develops artificial intelligence (AI) based software for guiding practitioners during prenatal ultrasound scans for secure prenatal screening. Its products include Sonio Diagnostics which combines a patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis during prenatal screening scans. The company was founded in 2020 and is based in Paris, France.